ALEXANDRIA, Va., Dec. 2 -- United States Patent no. 12,486,311, issued on Dec. 2, was assigned to Xencor Inc. (Pasadena, Calif.).
"CTLA4-Ig immunoadhesins" was invented by Gregory A. Lazar (Pacifica, Calif.) and Matthew J. Bernett (Monrovia, Calif.).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes."
The patent was filed on May 4, 2022, under Application No. 17/736,917.
*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&...